Compare Global X Autonomous & Electric Vehicles (DRIV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs ResMed Inc. — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.79 (market cap $356.37M), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 89.5× Global X Autonomous & Electric Vehicles's market cap, and ResMed Inc. pays a 1.16% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and ResMed Inc. for 51 Days on average.
| DRIV | RMD | |
|---|---|---|
Market Cap | $356.37M | $31.89B |
Volume | 22,397 | 618,314 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $275.96 |
52-Week Low | $27.58 | $182.82 |
Typical Hold Time | 40 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.60, down 2.29% today amid mixed technical signals with a bullish overall signal but bearish moving averages. The stock shows neutral momentum oscillators with RSI at 51.36 indicating balanced buying and selling pressure. Recent automotive sector news highlights hybrid vehicle momentum and China's ambitious EV targets, potentially benefiting automotive-focused ETFs.
The stock faces near-term resistance at $34 with technical indicators suggesting consolidation. Automotive sector transformation creates both opportunities from EV/hybrid adoption and risks from oil price volatility. Market sentiment remains divided as investors weigh technological shifts against traditional automotive challenges.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
